Abstract:Alexander Xiao, Christopher Warren, Waheeda Samady, Lucy Bilaver Northwestern University Feinberg School of Medicine, Center for Food Allergy and Asthma Research, Chicago, IL, USA Correspondence: Alexander Xiao Email There is a growing body of evidence that atopic skin disease may be due to disturbed microbial composition on the skin. 1 This dysbiosis has been observed in infants with eczema, with certain bacteria such as the Staphylococcal species playing an important role in the process. 2–4 In recent years, treatments for these conditions by altering the skin microbiome have been attempted with some success. One study found that intervention with topically applied R. mucosa was associated with decreased disease severity and S. aureus burden. 5 However, treatment with emollients, probiotic supplementation or "natural" remedies like tea tree oils have had limited evidence of efficacy. 1 Given this role the microbiome plays in atopic disease, our team has developed a novel, topical ointment primarily consisting of probiotics, honey, turmeric and B12 aimed at restoring a healthy skin microbiome. To examine its efficacy, we have completed the preliminary phases of a clinical trial. Our study was conducted as an Investigational New Drug with the FDA with approval from our Institutional IRB. Inclusion criteria were adults 18 and older with dry scalp and dandruff symptoms as determined by a trained research physician. Patients diagnosed with other scalp diseases such as psoriasis, tinea capitis, and pediculosis capitis, used systemic steroid or oral antibiotics in the past two months or had an allergy to any of the preparation components were excluded. Thirty-five adults (55% female, 40% White, 50% Asian, 5% Black, 5% Multiracial) with dry scalp were recruited and followed for this 2-week study. Participant median age was 26; IQR=8 years, range=20–78. The initial study visit consisted of a scalp exam and scalp photographs by a trained research physician to confirm that each participant had a dry scalp condition. At this time participants completed an intake survey including assessment of the participant demographics as well as the standardized assessments of scalp condition history and current symptoms described below. The scalp exam, photographs and intake survey provided the basis for our initial evaluation of disease and symptom severity through the Investigator Global Assessment (IGA), Total Severity Score (TSS) and Scalpdex. The IGA is a 5-point validated instrument that rates overall disease severity according to the following categories: 0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease. The TSS represents the sum of erythema, scaling, and pruritus severity scores of the scalp disease. A minimum TSS score is 0 (none) and the maximum TSS score is 9 (severe). Scalpdex is a validated 23-item quality-of-life questionnaire that is completed by participants to measure their subjective improvement with treatment. Participants were instructed to liberally apply the topical preparation to their scalp once daily for 14 days, leave in place for at least 7 minutes, and rinse in the shower. Participants returned after 14 days of treatment for an in-person follow up including a physician scalp assessment, end photograph and exit survey. At that point, the IGA, TSS and Scalpdex were again determined. Results from paired t -tests with one-sided p-values found that after 2 weeks of treatment, overall disease severity by IGA decreased from 2.1 at baseline to 1.1 at the end of the trial (t(34 df )=8.15; p<0.001). Additionally, mean TSS scores fell from 3.5 at baseline to 1.8 at the conclusion (t(34 df )= p<0.001). Overall Scalpdex decreased from 46.0 to 39.5 (t(33 df )=3.4; p=0.001, reflecting significant reductions in the subjective quality of life burden associated with the scalp condition ( Table 1 ). Notably, significant decreases were observed for all three TSS subscales (p erythema <0.001; p scaling <0.001; p pruritis <0.001) as well as all three Scalpdex subscales (p symptoms =0.001; p emotion <0.001; p functioning =0.04) ( Tables 1 and 2 ). Additionally, the intervention was well-tolerated, without adverse effects or complaints reported by any study participants. Table 1 IGA, TSS and Scalpdex Scores Before and After Intervention Table 2 Scalpdex Score Subscales Before and After Intervention Overall, our preliminary data found that use of a novel, topical dry scalp product clinically reduced the symptoms and disease severity of dry scalp -Abstract Truncated-

Clinical and Videodermoscopic Evaluation of the Efficacy, Safety, and Tolerability of a Shampoo Containing Ichthyol, Zanthalene, Mandelic Acid, and Honey in the Treatment of Scalp Psoriasis

Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

A New Purpose to Old Arsenal: Exploring the Safety and Efficacy of a New Regimen Comprising a Combination of Chlorhexidine Gluconate and Cetrimide for Seborrheic Dermatitis Treatment in a Randomized Placebo-Controlled Clinical Trial

Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis

Comparison of Safety and Efficacy Between Calcipotriol Plus Betamethasone Dipropionate Gel and Calcipotriol Scalp Solution As Long-Term Treatment for Scalp Psoriasis in Chinese Patients: a National, Multicentre, Prospective, Randomized, Active-Controlled Phase 4 Trial

The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study

Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice

An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults

Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris

Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study

Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers

In vivo Skin Penetration, Radical Protection, and Structural Changes after Topical Application of a Herbal Oil Cream Compared to Topical Calcipotriol in Mild to Moderate Psoriasis

A Topical Scalp Serum Containing Adenosine, MgSO4, Vitamin CG, and Pre- and Probiotic Fractions Reduces Discomfort and Associated Symptoms of Sensitive Scalp

Clinical and Biochemical Assessment of New-formula Shampoo for Scalp Seborrheic Dermatitis

Efficacy of Tazarotene 0.05%/betamethasone Dipropionate 0.05% Cream in the Treatment of Mild to Moderate Psoriasis Vulgaris: a Multicenter Clinical Observational Study

Continuous clinical improvement of mild‐to‐moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide–based shampoo after an initial treatment with ketoconazole

Clinical efficacy of a gentle anti‐dandruff itch‐relieving shampoo formulation

An open-label, investigator-initiated, single-center, prospective, pilot clinical study to evaluate the efficacy of a skin whitening serum applied twice daily combined with a spot-preventing SPF50+ sunscreen in healthy female subjects with melasma hyperpigmentation

Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study)

Novel Topical Treatment for Dandruff & Dry Scalp Through Sustained Balance in Skin Microbiome